Direct compression of calcium lactate gluconate for oral tablet manufacture starts with API pre-drying in a fluid-bed dryer at 45 °C until loss on drying is below 1.5% w/w, a threshold established to reduce capping on high-speed rotary presses. The dried material is passed through a 0.710 mm stainless-steel sieve and blended with microcrystalline cellulose PH 102 and spray-dried lactose monohydrate in a 600 L bin blender at 12 rpm for 20 min. Crospovidone is added at 2.5% w/w and magnesium stearate at 0.75% w/w; the final blend is compressed on a 45-station rotary tablet press at 15–25 kN compression force using 19 mm x 9 mm capsule-shaped tooling. Hardness is maintained at 8–12 kp and friability is controlled below 0.8% w/w after 100 rotations per USP <1216> and Ph Eur 2.9.7. Tablet mass is typically 1250 mg at 95% w/w drug loading to deliver approximately 150 mg elemental calcium, reflecting the 12.0–13.0% w/w elemental calcium content of the API. Uniformity of dosage units is evaluated according to USP <905> and Ph Eur 2.9.6, while dissolution is run in 900 mL 0.1 N hydrochloric acid at 37 °C with paddle speed 50 rpm per USP <711>. Because the API is hygroscopic, moisture-barrier blister packaging with silica gel desiccant is required where storage exceeds 25 °C/60% RH; residual moisture above 2.0% after 3 months at 40 °C/75% RH is a critical quality indicator for batch release. If direct compression shows capping at the upper compression force, the blend is switched to dry granulation by roller compaction and then compressed under the same tooling conditions.

What Causes Powder Bridging in Calcium Lactate Gluconate Capsule Filling?

Automatic capsule filling of unmodified calcium lactate gluconate powder is constrained by the same hygroscopicity that affects direct compression. The API forms agglomerates above 55% RH; powder bridging in the dosing disc is observed on MG2 and Bosch GKF capsule fillers when flowability falls below a Carr index of 25% as determined by USP <1174>. Dry granulation by roller compaction is therefore used before filling. The API is compacted at 30–40 kN roll force with microcrystalline cellulose and croscarmellose sodium, then milled through a 0.800 mm screen. The granulate is filled into hard gelatin or HPMC capsules at target fill weight 600–700 mg using a dosator-type machine; weight variation is controlled under USP <905> and disintegration is tested with sinkers in water at 37 °C per USP <701>. The fill formulation contains 0.5% w/w sodium stearyl fumarate instead of magnesium stearate to avoid delayed dissolution caused by hydrophobic lubrication. Capsules are packaged in PVC/PVDC blisters with desiccant because moisture uptake above 2.0% causes shell brittleness and delayed disintegration.

Wet granulation of calcium lactate gluconate for single-dose granules or sachets operates within a narrow liquid addition window because the API dissolves partially in the binder solution. A binder solution of povidone K-30 at 5% w/w in purified water is sprayed at 20–30 g/min into a rapid mixer granulator; when the liquid-to-solid ratio exceeds 0.35 mL/g, the mass over-wets and produces granules larger than 1000 µm, which slows reconstitution in water. Granulation is stopped at a moisture content of 8–10% w/w and the wet mass is discharged through a 2.0 mm screen, then dried in a fluid-bed dryer at 60 °C inlet air until loss on drying is below 1.5% w/w. The dried granules are sieved to 200–710 µm, blended with sucrose or maltodextrin, anhydrous citric acid, and flavor, and filled into 3–5 g sachets. Reconstitution in 150 mL water at 15–25 °C is assessed visually; a clear dispersion should form within 60 s. Loss on drying is tested per USP <731> and Ph Eur 2.2.32, and microbial limits are controlled under USP <61> and <62>. The main process failure mode is residual moisture above 2.0% causing caking and brown specks when reducing sugars are present in the formulation; anhydrous excipients and desiccant sachets are used to control that boundary.

When Calcium Lactate Gluconate Replaces Calcium Gluconate in Oral Solutions

In oral solutions, calcium lactate gluconate is dissolved in purified water at 25–40 °C under continuous stirring; the dissolution rate depends on the initial particle size and the pH of the buffer system. Target calcium concentration is limited to 10–20 mg elemental calcium per 5 mL because higher concentrations can form calcium gluconate complexes that raise viscosity and reduce clarity. The solution pH is adjusted to 4.0–5.5 with lactic acid or sodium hydroxide, a range that balances calcium ion availability and preservative efficacy. Potassium sorbate 0.1% w/w is preferred over sodium benzoate when the pH is above 4.5 to avoid precipitation of benzoic acid in cold storage. The final solution is filled into 100 mL amber PET or Type III glass bottles; content uniformity is ensured by continuous nitrogen sparging during manufacturing to minimize oxidation of gluconate-derived components. Antimicrobial effectiveness is verified per Ph Eur 5.1.3 and USP <51>. Accelerated stability is performed at 40 °C/75% RH for 6 months; published data for this specific configuration is limited, so a bracketed matrix at pH 4.0, 4.5, and 5.0 is recommended. Phosphate buffers are not used because calcium phosphate precipitates below pH 6.5.

Injectable Calcium Salt Selection and Terminal Sterilization Boundaries

Calcium lactate gluconate for injectable use is evaluated under the same particulate, endotoxin, and sterility requirements as calcium gluconate injection. Published data for this specific salt in commercial parenteral formulations is limited, so formulation development must be driven by compatibility screening rather than compendial precedent. The API is dissolved in water for injection at a concentration equivalent to 9–10 mg elemental calcium per 10 mL; the solution is filtered through a 0.22 µm PVDF membrane and filled into Type I borosilicate glass vials in an ISO Class 5 environment per ISO 14644-1:2015. Terminal sterilization at 121 °C for 15 min is applied only after confirming that no precipitation occurs at the selected pH; calcium salts can precipitate as calcium hydroxide or carbonate when the solution is exposed to atmospheric carbon dioxide above pH 7.0. pH is adjusted to 6.0–6.5 with dilute hydrochloric acid or sodium hydroxide. The container closure is a halobutyl rubber stopper with an inert fluoropolymer coating to reduce extractables. USP <788> particulate matter and Ph Eur 2.9.19 are applied to each batch; bacterial endotoxins are controlled under USP <85> and Ph Eur 2.6.14. Sterility test is performed per USP <71> and Ph Eur 2.6.1. The product is for single-dose administration only; no antimicrobial preservative is permitted. Incompatibility with phosphate-containing IV solutions is critical: mixing calcium salt with sodium phosphate or bicarbonate-containing IV fluids can form precipitates within seconds at pH above 6.0, so a dedicated IV line is required after administration. Terminal sterilization validation follows 21 CFR 211.110 and 21 CFR 211.165.

Effervescent Granulation Routes Are Constrained by Acid-Base Compatibility

Effervescent dosage forms containing calcium lactate gluconate are manufactured by dry granulation or melt granulation because any free water initiates the citric acid–sodium bicarbonate reaction during processing. The API, extruded and sieved to 100–315 µm, is mixed with anhydrous citric acid, sodium bicarbonate, sorbitol, and 0.5% w/w polyethylene glycol 6000 as melt binder. The blend is heated to 55–60 °C under low-shear mixing, then cooled and screened through 1.0 mm. The granulate is compressed on a rotary press at 10–15 kN into 25 mm flat-faced tablets of 4.0–4.5 g total weight. Effervescence time is measured in 200 mL water at 15–25 °C; dissolution is considered complete when gas evolution stops and the solution is clear. Sodium bicarbonate is charged in 10% molar excess over anhydrous citric acid to avoid residual acidity, and moisture in the granulate is held below 0.5% w/w by loss on drying per USP <731>. Tablets are packaged in aluminum tubes with silica gel stopper; residual moisture above 0.8% causes premature effervescence and browning. The main incompatibility is with citric acid monohydrate, which releases crystalline water at 55 °C and triggers the reaction; only anhydrous citric acid is used.